The roles of β-tubulin mutations and isotype expression in acquired drug resistance

Cancer Informatics

Volumn 3, Issue , 2007, Pages 159-181

  Huzil, J Torin ^a   Chen, Ke ^a   Kurgan, Lukasz ^a   Tuszynski, Jack A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Cancer; Isotype; Microtubule; Mutant; Paclitaxel; Resistance; Tubulin

Indexed keywords

ALPHA TUBULIN; ANTINEOPLASTIC AGENT; BETA TUBULIN; COLCHICINE; DIMER; DOCETAXEL; EPOTHILONE DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE DIPHOSPHATE; PACLITAXEL; TAXANE DERIVATIVE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

CANCER RESISTANCE; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; GENE EXPRESSION; GENE MUTATION; HUMAN; MICROTUBULE ASSEMBLY; NONHUMAN; PHARMACOGENETICS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMERIZATION; PROTEIN STRUCTURE; REVIEW; AMINO ACID SUBSTITUTION; BETA TUBULIN GENE; CARBOXY TERMINAL SEQUENCE; DRUG DNA INTERACTION; DRUG METABOLISM; DRUG UPTAKE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; MICROTUBULE; MUTATIONAL ANALYSIS; PREDICTIVE VALUE; PROTEIN DOMAIN; STRUCTURE ANALYSIS;

EID: 49649097047     PISSN: 11769351     EISSN: 11769351     Source Type: Journal    
DOI: 10.1177/117693510700300028     Document Type: Review

References (113)

1. Achiwa, H. et al. 2003. Analysis of beta-tubulin gene alteration in human lung cancer cell lines. Cancer Lett., 201:211-216.
2. Amos, L.A. and Lowe, J. 1999. How Taxol stabilises microtubule structure. Chem. Biol., 6:R65-9.
3. Bai, R. 1999. Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: Comparison with dolastatin 10 and cryptophycin 1. Biochemistry, 38:14302-14310.
4. Banerjee, A. and Kasmala, L.T. 1998. Differential assembly kinetics of alpha-tubulin isoforms in the presence of paclitaxel. Biochem. Biophys. Res. Commun., 245:349-351.
5. Banerjee, A. and Luduena, R.F. 1992. Kinetics of colchicine binding to purified beta-tubulin isotypes from bovine brain. J. Biol. Chem., 267:13335-13339.
6. Banerjee, A. et al. 1990. Increased microtubule assembly in bovine brain tubulin lacking the type III isotype of beta-tubulin. J. Biol. Chem., 265:1794-1799.
7. Barlow, S.B., Gonzalez-Garay, M.L. and Cabral, F. 2002. Paclitaxel-dependent mutants have severely reduced microtubule assembly and reduced tubulin synthesis. J. Cell. Sci., 115:3469-3478.
8. Bayley, P.M., Schilstra, M.J. and Martin, S.R. 1990. Microtubule dynamic instability: numerical simulation of microtubule transition properties using a Lateral Cap model. J. Cell. Sci., 95:33-48.
9. Berrieman, H.K., Lind, M.J. and Cawkwell, L. 2004. Do beta-tubulin mutations have a role in resistance to chemotherapy? Lancet. Oncol., 5:158-164.
10. Blade, K., Menick, D.R. and Cabral, F. 1999. Overexpression of class I, II or IVb beta-tubulin isotypes in CHO cells is insufficient to confer resistance to paclitaxel. J. Cell. Sci., 112:2213-2221.
11. Boggs, B. and Cabral, F. 1987. Mutations affecting assembly and stability of tubulin: evidence for a nonessential beta-tubulin in CHO cells. Mol. Cell. Biol., 7:2700-2707.
12. Bollag, D.M. et al. 1995. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res., 55:2325-2333.
13. Burkhart, C.A., Kavallaris, M. and Band Horwitz, S. 2001. The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim. Biophys. Acta., 1471:O1-9.
14. Cabral, F., Abraham, I. and Gottesman, M.M. 1982. Revertants of a Chinese hamster ovary cell mutant with an altered beta-tubulin: evidence that the altered tubulin confers both colcemid resistance and temperature sensitivity on the cell. Mol. Cell. Biol., 2:720-729.
15. Cabral, F. and Barlow, S.B. 1989. Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly. FASEB. J., 3:1593-1599.
16. Cabral, F., Sobel, M.E. and Gottesman, M.M. 1980. CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered beta-tubulin. Cell., 20:29-36.
17. Carles, G. et al. 1999. Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs. Br. J. Cancer, 80:1162-1168.
18. Cowan, N.J. and Dudley, L. 1983. Tubulin isotypes and the multigene tubulin families. Int. Rev. Cytol., 85:147-173.
19. D'Amato, R.J. et al. 1994. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Natl. Acad. Sci. U.S.A., 91:3964-3968.
20. de Castro, J. et al. 2003. New insights in beta-tubulin sequence analysis in non-small cell lung cancer. Lung. Cancer, 41:41-48.
21. Derry, W.B. et al. 1997. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry, 36, 3554-3562.
22. Dozier, J.H. et al. 2003. Beta class II tubulin predominates in normal and tumor breast tissues. Breast Cancer Res., 5:R157-69.
23. Drechsel, D.N. et al. 1992. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol. Biol. Cell., 3:1141-1154.
24. Dumontet, C. et al. 1996. Differential expression of tubulin isotypes during the cell cycle. Cell. Motil. Cytoskeleton, 35:49-58.
25. Ferguson, R.E. et al. 2005. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression. Clin. Cancer Res., 11:3439-3445.
26. Fourest-Lieuvin, A. et al. 2006. Microtubule regulation in mitosis: tubulin phosphorylation by the cyclin-dependent kinase Cdk1. Mol. Biol. Cell., 17:1041-1050.
27. Giannakakou, P. et al. 2000. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc. Natl. Acad. Sci. U.S.A., 97:2904-2909.
28. Giannakakou, P. et al. 1997. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J. Biol. Chem., 272:17118-17125.
29. Gigant, B. et al. 2000. The 4 A X-ray structure of a tubulin:stathmin- like domain complex. Cell, 102:809-816.
30. Gigant, B. et al. 2005. Structural basis for the regulation of tubulin by vinblastine. Nature, 435:519-522.
31. Gokmen-Polar, Y. et al. 2005. beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Cancer Res., 65:9406-9414.
32. Gonzalez-Garay, M.L. and Cabral, F. 1995. Overexpression of an epitope-tagged beta-tubulin in Chinese hamster ovary cells causes an increase in endogenous alpha-tubulin synthesis. Cell. Motil. Cytoskeleton, 31:259-272.
33. Gonzalez-Garay, M.L. and Cabral, F. 1996. alpha-Tubulin limits its own synthesis: evidence for a mechanism involving translational repression. J. Cell. Biol., 135:1525-1534.
34. Gonzalez-Garay, M.L. et al. 1999. A beta-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J. Biol. Chem., 274:23875-23882.
35. Gupta, M.L.J. et al. 2001. Mutagenesis of beta-tubulin cysteine residues in Saccharomyces cerevisiae: mutation of cysteine 354 results in cold-stable microtubules. Cell. Motil. Cytoskeleton, 49:67-77.
36. Haber, M. et al. 1995. Altered expression of M beta 2, the class II beta-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J. Biol. Chem., 270:31269-31275.
37. Hari, M. et al. 2003b. Mutations in alpha- and beta-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol. Cancer Ther., 2:597-605.
38. Hari, M. et al. 2003a. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell. Motil. Cytoskeleton, 56:45-56.
39. Hasegawa, S. et al. 2002. Mutational analysis of the class I beta-tubulin gene in human breast cancer. Int. J. Cancer, 101:46-51.
40. He, L., Yang, C.P. and Horwitz, S.B. 2001. Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol. Cancer Ther., 1:3-10.
41. Horio, T. and Hotani, H. 1986. Visualization of the dynamic instability of individual microtubules by dark-field microscopy. Nature, 321:605-607.
42. Huzil, J.T., Luduena, R.F. and Tuszynski, J.A. 2006. Comparative modelling of human and beta; tubulin isotypes and implications for drug binding. Nanotechnology, 17:S90.
43. Hyams, J.S. and Stebbings, H. 1979. The mechanism of microtubule associated cytoplasmic transport. Isolation and preliminary characterisation of a microtubule transport system. Cell. Tissue. Res., 196:103-116.
44. Jensen-Smith, H.C., Luduena, R.F. and Hallworth, R. 2003. Requirement for the beta I and beta IV tubulin isotypes in mammalian cilia. Cell. Motil. Cytoskeleton, 55:213-220.
45. Jordan, M. and Wilson, L. 2004. Mary Ann Jordan, Leslie Wilson. Nat. Rev. Cancer, 4:253-265.
46. Kamath, K. et al. 2005. β III-Tubulin Induces Paclitaxel Resistance in Association with Reduced Effects on Microtubule Dynamic Instability. J. Biol. Chem., 280:12902-12907.
47. Katsetos, C.D., Herman, M.M. and Mork, S.J. 2003. Class III beta-tubulin in human development and cancer. Cell. Motil. Cytoskeleton, 55:77-96.
48. Kavallaris, M., Burkhart, C.A. and Horwitz, S.B. 1999. Antisense oligonucleotides to class III beta-tubulin sensitize drug-resistant cells to Taxol. Br. J. Cancer, 80:1020-1025.
49. Kavallaris, M. et al. 1997. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J. Clin. Invest., 100:1282-1293.
50. Kavallaris, M. et al. 2001. Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. Cancer Res., 61:5803-5809.
51. Keates, R.A., Sarangi, F. and Ling, V. 1981. Structural and functional alterations in microtubule protein from Chinese hamster ovary cell mutants. Proc. Natl. Acad. Sci. U.S.A., 78:5638-5642.
52. Kemphues, K.J. et al. 1982. The testis-specific beta-tubulin subunit in Drosophila melanogaster has multiple functions in spermatogenesis. Cell., 31:655-670.
53. Keskin, O. et al. 2002. Relating molecular flexibility to function: a case study of tubulin. Biophys. J., 83:663-680.
54. Klein, L.E. et al. 2005. The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence. Cell. Cycle., 4:501-507.
55. Kurz, J.C. and Williams, R.C.J. 1995. Microtubule-associated proteins and the flexibility of microtubules. Biochemistry, 34:13374-13380.
56. Li, H. et al. 2002. Microtubule structure at 8 A resolution. Structure (Camb), 10:1317-1328.
57. Ling, V. et al. 1979. Mutants of Chinese hamster ovary (CHO) cells with altered colcemid-binding affinity. Cell., 18:423-430.
58. Liu, B. et al. 2001. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J. Surg. Res., 99:179-186.
59. Lowe, J. et al. 2001. Refined structure of alpha beta-tubulin at 3.5 A resolution. J. Mol. Biol., 313:1045-1057.
60. Lu, Q. and Luduena, R.F. 1994. In vitro analysis of microtubule assembly of isotypically pure tubulin dimers. Intrinsic differences in the assembly properties of alpha beta II, alpha beta III, and alpha beta IV tubulin dimers in the absence of microtubule-associated proteins. J. Biol. Chem., 269:2041-2047.
61. Luduena, R.F. 1998. Multiple forms of tubulin: different gene products and covalent modifications. Int. Rev. Cytol., 178:207-275.
62. MacRae, T.H. 1997. Tubulin post-translational modifications - enzymes and their mechanisms of action. Eur. J. Biochem., 244:265-278.
63. Maeno, K. et al. 2003. Mutation of the class I beta-tubulin gene does not predict response to paclitaxel for breast cancer. Cancer Lett., 198:89-97.
64. Mandelkow, E.M. and Mandelkow, E. 1992. Microtubule oscillations. Cell. Motil. Cytoskeleton, 22:235-244.
65. Margolis, R.L. and Wilson, L. 1981. Microtubule treadmills-possible molecular machinery. Nature, 293:705-711.
66. Melki, R. et al. 1989. Cold depolymerization of microtubules to double rings: geometric stabilization of assemblies. Biochemistry, 28:9143-9152.
67. Mesquita, B. et al. 2005. No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/ cisplatin. BMC. Cancer, 5:101.
68. Minotti, A.M., Barlow, S.B. and Cabral, F. 1991. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J. Biol. Chem., 266:3987-3994.
69. Mitchison, T. and Kirschner, M. 1984. Dynamic instability of microtubule growth. Nature, 312:237-242.
70. Monzo, M. et al. 1999 Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J. Clin. Oncol., 17:1786-1793.
71. Mozzetti, S. et al. 2005. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res., 11:298-305.
72. Nettles, J.H. et al. 2004. The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography. Science, 305:866-869.
73. Nicoletti, M.I. et al. 2001. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. Clin. Cancer Res., 7:2912-2922.
74. Nogales, E., Wolf, S.G. and Downing, K.H. 1998. Structure of the alpha beta tubulin dimer by electron crystallography. Nature, 391:199-203.
75. Nogales, E. et al. 1995. Structure of tubulin at 6.5 A and location of the taxol-binding site. Nature, 375:424-427.
76. Odde, D.J., Cassimeris, L. and Buettner, H.M. 1995. Kinetics of microtubule catastrophe assessed by probabilistic analysis. Biophys. J., 69:796-802.
77. Panda, D. et al. 1994. Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc. Natl. Acad. Sci. U.S.A., 91:11358-11362.
78. Pichichero, M.E. and Avers, C.J. 1973. The evolution of cellular movement in eukaryotes: the role of microfilaments and microtubules. Subcell. Biochem., 2:97-105.
79. Poruchynsky, M.S. et al. 2004. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. Biochemistry, 43:13944-13954.
80. Prasannan, L. et al. 2000. Identification of beta-tubulin isoforms as tumor antigens in neuroblastoma. Clin. Cancer Res., 6:3949-3956.
81. Ranganathan, S. et al. 1998. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br. J. Cancer, 77:562-566.
82. Ranganathan, S. et al. 1996. Increase of beta(III)- and beta(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res., 56:2584-2589.
83. Ravelli, R.B. et al. 2004. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature, 428, 198-202.
84. Richards, K.L. et al. 2000. Structure-function relationships in yeast tubulins. Mol. Biol. Cell., 11:1887-1903.
85. Ringel, I. and Horwitz, S.B. 1991. Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. J. Natl. Cancer Inst., 83:288-291.
86. Roach, M.C. et al. 1998. Preparation of a monoclonal antibody specific for the class I isotype of beta-tubulin: the beta isotypes of tubulin differ in their cellular distributions within human tissues. Cell. Motil. Cytoskeleton, 39:273-285.
87. Rowinsky EK, et al. 1989. Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res., 49:4640-7.
88. Sale, S. et al. 2002. Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers. Mol. Cancer Ther., 1:215-225.
89. Sangrajrang, S. et al. 1998. Association of estramustine resistance in human prostatic carcinoma cells with modified patterns of tubulin expression. Biochem. Pharmacol., 55:325-331.
90. Schiff, P.B. and Horwitz, S.B. 1980. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. U.S.A., 77:1561-1565.
91. Scott, C.A. et al. 1990. Beta-tubulin epitope expression in normal and malignant epithelial cells. Arch. Otolaryngol Head. Neck. Surg., 116:583-589.
92. Shalli, K. et al. 2005. Alterations of beta-tubulin isotypes in breast cancer cells resistant to docetaxel. FASEB. J., 19:1299-1301.
93. Soucek, K. et al. 2006. Normal and prostate cancer cells display distinct molecular profiles of alpha-tubulin posttranslational modifications. Prostate, 66:954-965.
94. Spiegelman, B.M., Penningroth, S.M. and Kirschner, M.W. 1977. Turnover of tubulin and the N site GTP in Chinese hamster ovary cells. Cell., 12:587-600.
95. Sullivan, K.F. and Cleveland, D.W. 1986. Identification of conserved isotype-defining variable region sequences for four vertebrate beta tubulin polypeptide classes. Proc. Natl. Acad. Sci. U.S.A., 83:4327-4331.
96. Theodorakis, N.G. and Cleveland, D.W. 1992. Physical evidence for co-translational regulation of beta-tubulin mRNA degradation. Mol. Cell. Biol., 12:791-799.
97. Thompson, J.D., Higgins, D.G. and Gibson, T.J. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic. Acids. Res., 22:4673-4680.
98. Toso, R.J. et al. 1993. Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine. Biochemistry, 32:1285-1293.
99. Tsurutani, J. et al. 2002. Mutational analysis of the beta-tubulin gene in lung cancer. Lung. Cancer, 35:11-16.
100. Unger, E., Bohm, K.J. and Vater, W. 1990. Structural diversity and dynamics of microtubules and polymorphic tubulin assemblies. Electron. Microsc. Rev., 3:355-395.
101. VanBuren, V., Odde, D.J. and Cassimeris, L. 2002. Estimates of lateral and longitudinal bond energies within the microtubule lattice. Proc. Natl. Acad. Sci., U.S.A., 99, 6035-6040.
102. Verdier-Pinard, P. et al. 2003. Direct analysis of tubulin expression in cancer cell lines by electrospray ionization mass spectrometry. Biochemistry, 42:12019-12027.
103. Verrills, N.M. et al. 2003. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem. Biol., 10:597-607.
104. Walker, R.A., Pryer, N.K. and Salmon, E.D. 1991. Dilution of individual microtubules observed in real time in vitro: evidence that cap size is small and independent of elongation rate. J. Cell. Biol., 114:73-81.
105. Wang, H.W. and Nogales, E. 2005. Nucleotide-dependent bending flexibility of tubulin regulates microtubule assembly. Nature, 435:911-915.
106. Wang, Y., Veeraraghavan, S. and Cabral, F. 2004. Intra-allelic suppression of a mutation that stabilizes microtubules and confers resistance to colcemid. Biochemistry, 43:8965-8973.
107. Wani, M.C. et al. 1971. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc., 93:2325-2327.
108. Weisenberg, R.C., Deery, W.J. and Dickinson, P.J. 1976. Tubulin-nucleotide interactions during the polymerization and depolymerization of microtubules. Biochemistry, 15:4248-4254.
109. Westermann, S. et al. 2006. The Dam1 kinetochore ring complex moves processively on depolymerizing microtubule ends. Nature, 440:565-569.
110. Westermann, S. and Weber, K. 2003. Post-translational modifications regulate microtubule function. Nat. Rev. Mol. Cell. Biol., 4:938-947.
111. Xiao, H. et al. 2006. Insights into the mechanism of microtubule stabilization by Taxol. Proc. Natl. Acad. Sci. U.S.A., 103:10166-10173.
112. Yang, C.P. et al. 2005. A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence. Mol. Cancer Ther., 4:987-995.
113. Zheng, Y. et al. 1995. Nucleation of microtubule assembly by a gamma-tubulin-containing ring complex. Nature, 378:578-583.